SNCA and Parkinson disease: Studies using animal models support that therapeutics lowering overall SNCA expression may improve PD phenotypes, even when treatment begins after disease onset: In a mouse model of Lewy body disease, with inducible A53T-SNCA expression, transgene suppression improved learning and memory phenotypes and reduced Lewy body-like aggregates in cortex and hippocampus (17).